Crucially, objective tumor responses (ORR according to RECIST) have also been documented, with rates spanning from approximately 10% in some initial PSMA trials to encouraging figures exceeding 40% in higher-dose cohorts of the STEAP1-targeting Xaluritamig study [12,19]. This evidence concerns the gene FOLH1 and neoplasm.